Plasma provided by COVID‐19 convalescent patients may provide therapeutic relief as the
number of COVID‐19 cases escalates steeply worldwide. Prior findings in various viral …

With a prevalence affecting over 30% of HIV infected patients, coinfection with hepatitis B (HBV)
or C (HCV) virus remains one of the most frequent comorbidities in this population, with …

Anti-CD20 monoclonal antibodies are widely used for the treatment of hematological
malignancies or autoimmune disease but may be responsible for a secondary humoral deficiency. …

Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …

Background & Aims Moderate cure rates of acute hepatitis C virus (HCV) infections with
pegylated interferon and ribavirin have been described in the last decade in men who have sex …

Objectives To determine whether hydroxychloroquine decreases the risk of adverse outcome
in patients with mild to moderate coronavirus disease 2019 (COVID-19) at high risk of …

Background Lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a and hydroxychloroquine
efficacy for COVID-19 have been evaluated, but detailed evaluation is lacking. Objective …

Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …

Importance Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common
presentation of coronavirus disease 2019 (COVID-19). Objective To determine whether …

Background. Campylobacter bacteremia is uncommon. The influence of underlying
conditions and of the impact of antibiotics on infection outcome are not known. Methods. From …